First FDA-Approved Biosimilar Rx Drug Enters Market
The first FDA-approved biosimilar medication, Novartis' Zarxio, entered the market on Thursday, sparking a new era of competition between high-cost biologic treatments and similar, lower-cost medications. Zarxio was introduced with a wholesale price of $275.66 for one 300 microgram syringe and $438.98 for a 480 mcg dose. Zarxio's introduction to the market could clear the way for other biosimilars that are currently under review.
- "Sandoz Launches Sale of Biosimilar Zarxio" (Ross Johnson, Modern Healthcare, 9/3).